187 related articles for article (PubMed ID: 12957441)
1. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients.
Koh KK; Ahn JY; Han SH; Kim DS; Jin DK; Kim HS; Shin MS; Ahn TH; Choi IS; Shin EK
J Am Coll Cardiol; 2003 Sep; 42(5):905-10. PubMed ID: 12957441
[TBL] [Abstract][Full Text] [Related]
2. Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients.
Koh KK; Quon MJ; Han SH; Chung WJ; Ahn JY; Kim JA; Lee Y; Shin EK
Diabetes Care; 2006 Feb; 29(2):195-201. PubMed ID: 16443859
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients.
Koh KK; Quon MJ; Han SH; Chung WJ; Lee Y; Shin EK
Int J Cardiol; 2006 Mar; 108(1):96-100. PubMed ID: 16246439
[TBL] [Abstract][Full Text] [Related]
4. Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension.
Fogari R; Zoppi A; Salvadeo SA; Mugellini A; Lazzari P; Santoro T; Derosa G
Hypertens Res; 2011 Apr; 34(4):509-15. PubMed ID: 21179101
[TBL] [Abstract][Full Text] [Related]
5. Effect of the angiotensin II receptor blocker candesartan on fibrinolysis in patients with mild hypertension.
Skurk T; Lee YM; Nicuta-Rölfs TO; Haastert B; Wirth A; Hauner H
Diabetes Obes Metab; 2004 Jan; 6(1):56-62. PubMed ID: 14686964
[TBL] [Abstract][Full Text] [Related]
6. Effects of candesartan and lisinopril on the fibrinolytic system in hypertensive patients.
Hirschl MM; Bur A; Woisetschlaeger C; Derhaschnig U; Laggner AN
J Clin Hypertens (Greenwich); 2007 Jun; 9(6):430-5. PubMed ID: 17541328
[TBL] [Abstract][Full Text] [Related]
7. Candesartan reduces oxidative stress and inflammation in patients with essential hypertension.
Dohi Y; Ohashi M; Sugiyama M; Takase H; Sato K; Ueda R
Hypertens Res; 2003 Sep; 26(9):691-7. PubMed ID: 14620923
[TBL] [Abstract][Full Text] [Related]
8. Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension.
Koh KK; Han SH; Chung WJ; Ahn JY; Jin DK; Kim HS; Park GS; Kang WC; Ahn TH; Shin EK
Am J Cardiol; 2004 Jun; 93(11):1432-5, A10. PubMed ID: 15165934
[TBL] [Abstract][Full Text] [Related]
9. [Effect of angiotensin II type 1 receptor antagonist on oxidative stress markers in type 2 diabetic patients with hypertension].
Sato N; Kase H; Kato T; Kasai K
Nihon Rinsho; 2003 Jul; 61(7):1245-9. PubMed ID: 12877092
[TBL] [Abstract][Full Text] [Related]
10. Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies.
Wei F; Jia XJ; Yu SQ; Gu Y; Wang L; Guo XM; Wang M; Zhu F; Cheng X; Wei YM; Zhou ZH; Fu M; Liao YH;
Heart; 2011 Mar; 97(6):479-84. PubMed ID: 21296780
[TBL] [Abstract][Full Text] [Related]
11. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension.
Yu Y; Fukuda N; Yao EH; Matsumoto T; Kobayashi N; Suzuki R; Tahira Y; Ueno T; Matsumoto K
Am J Hypertens; 2008 Jan; 21(1):72-7. PubMed ID: 18091747
[TBL] [Abstract][Full Text] [Related]
12. Candesartan cilexetil and renal hemodynamics in hypertensive patients.
Fridman K; Wysocki M; Friberg P; Andersson OK
Am J Hypertens; 2000 Sep; 13(9):1045-8. PubMed ID: 10981559
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction.
Wassmann S; Hilgers S; Laufs U; Böhm M; Nickenig G
Arterioscler Thromb Vasc Biol; 2002 Jul; 22(7):1208-12. PubMed ID: 12117739
[TBL] [Abstract][Full Text] [Related]
14. Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade.
Schiffrin EL; Touyz RM
J Am Coll Cardiol; 2003 Sep; 42(5):911-3. PubMed ID: 12957442
[No Abstract] [Full Text] [Related]
15. Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure.
Sakamoto M; Suzuki H; Hayashi T; Iuchi H; Isaka T; Sakamoto N; Kayama Y; Tojo K; Yoshimura M; Utsunomiya K
Cardiovasc Diabetol; 2012 Oct; 11():118. PubMed ID: 23034088
[TBL] [Abstract][Full Text] [Related]
16. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study.
London G; Schmieder R; Calvo C; Asmar R
Am J Hypertens; 2006 Jan; 19(1):113-21. PubMed ID: 16461202
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators.
Lacourcière Y; Asmar R
Am J Hypertens; 1999 Dec; 12(12 Pt 1-2):1181-7. PubMed ID: 10619580
[TBL] [Abstract][Full Text] [Related]
18. Effects of angiotensin II (AT1) receptor blockade on cardiac vagal control in heart failure.
Vaile JC; Chowdhary S; Osman F; Ross HF; Fletcher J; Littler WA; Coote JH; Townend JN
Clin Sci (Lond); 2001 Dec; 101(6):559-66. PubMed ID: 11724639
[TBL] [Abstract][Full Text] [Related]
19. [Protective vascular effect of angiotensin receptor blocker (ARB)].
Yamakado M
Nihon Rinsho; 2002 Oct; 60(10):2020-7. PubMed ID: 12397701
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study.
Koh KK; Chung WJ; Ahn JY; Han SH; Kang WC; Seo YH; Ahn TH; Choi IS; Shin EK
Atherosclerosis; 2004 Nov; 177(1):155-60. PubMed ID: 15488878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
